Translator Disclaimer
1 March 2012 Pyriproxyfen for the Control of Australian Salt-Marsh Mosquito, Aedes vigilax
Author Affiliations +
Abstract

The efficacy of pyriproxyfen against the Australian salt-marsh mosquito, Aedes vigilax, was examined in 2 laboratory and 1 semi-field study using both technical grade and formulated products. In a dose–response study, the median emergence inhibition (EI50) and EI95 values were determined to be 0.019 and 0.076 ppb, respectively, for pyriproxyfen technical grade, 0.021 and 0.092 ppb for a microencapsulated formulation (Sumilarv® 90CS), and 0.054 and 0.236 ppb for the formulated s-methoprene product, Altosid™ Liquid Larvicide. A further laboratory comparison of the microencapsulated formulation of pyriproxyfen and Altosid, at the nominal field rate for Altosid, showed that both products provided 100% emergence inhibition and this was confirmed in a semi-field study, which also included a granular formulation of pyriproxyfen (Sumilarv 0.5G).

Garry Webb, Peter Miller, and Bryce Peters "Pyriproxyfen for the Control of Australian Salt-Marsh Mosquito, Aedes vigilax," Journal of the American Mosquito Control Association 28(1), 50-52, (1 March 2012). https://doi.org/10.2987/11-6139.1
Published: 1 March 2012
JOURNAL ARTICLE
3 PAGES

This article is only available to subscribers.
It is not available for individual sale.
+ SAVE TO MY LIBRARY

SHARE
ARTICLE IMPACT
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top